Janus Henderson Group PLC Invests $658,000 in Corcept Therapeutics Incorporated (CORT)

Janus Henderson Group PLC acquired a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 56,017 shares of the biotechnology company’s stock, valued at approximately $658,000.

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Corcept Therapeutics by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 10,362,560 shares of the biotechnology company’s stock worth $145,283,000 after acquiring an additional 37,781 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Corcept Therapeutics by 6.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,903,036 shares of the biotechnology company’s stock worth $25,424,000 after acquiring an additional 120,758 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Corcept Therapeutics by 3.2% during the 4th quarter. Bank of New York Mellon Corp now owns 1,341,941 shares of the biotechnology company’s stock worth $17,929,000 after acquiring an additional 42,227 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Corcept Therapeutics by 7.9% during the 4th quarter. Geode Capital Management LLC now owns 1,175,034 shares of the biotechnology company’s stock worth $15,698,000 after acquiring an additional 85,705 shares during the period. Finally, AMI Asset Management Corp lifted its holdings in shares of Corcept Therapeutics by 19.9% during the 4th quarter. AMI Asset Management Corp now owns 754,805 shares of the biotechnology company’s stock worth $10,084,000 after acquiring an additional 125,444 shares during the period. Institutional investors and hedge funds own 78.77% of the company’s stock.

NASDAQ CORT opened at $10.20 on Thursday. Corcept Therapeutics Incorporated has a one year low of $9.14 and a one year high of $20.00. The company has a market capitalization of $1.22 billion, a P/E ratio of 17.00 and a beta of 1.26.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.15 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.03). Corcept Therapeutics had a net margin of 29.52% and a return on equity of 28.66%. The business had revenue of $64.80 million during the quarter, compared to analysts’ expectations of $69.29 million. During the same quarter in the previous year, the business posted $0.14 EPS. The company’s quarterly revenue was up 12.4% on a year-over-year basis. As a group, equities analysts expect that Corcept Therapeutics Incorporated will post 0.79 EPS for the current fiscal year.

Several research analysts have recently weighed in on CORT shares. TheStreet lowered shares of Corcept Therapeutics from a “b” rating to a “c+” rating in a report on Friday, May 10th. B. Riley set a $11.00 price target on shares of Corcept Therapeutics and gave the company a “hold” rating in a report on Tuesday, February 5th. ValuEngine upgraded shares of Corcept Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, March 1st. Cantor Fitzgerald set a $14.00 price target on shares of Corcept Therapeutics and gave the company a “hold” rating in a report on Tuesday, February 26th. Finally, BidaskClub upgraded shares of Corcept Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 11th. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $12.50.

TRADEMARK VIOLATION NOTICE: “Janus Henderson Group PLC Invests $658,000 in Corcept Therapeutics Incorporated (CORT)” was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.themarketsdaily.com/2019/05/23/janus-henderson-group-plc-invests-658000-in-corcept-therapeutics-incorporated-cort.html.

About Corcept Therapeutics

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.

See Also: Cash Flow

Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.